MAPT and Alzheimer disease: Secondary outcomes included change in scores on the CDR-SB, ADAS-Cog13, MMSE, and Alzheimer’s Disease Cooperative Study - Instrumental Activities of Daily Living (ADCS-iADL), along with changes in amyloid and tau levels.